Fosun to Develop Drugs, Devices With New U.S. Unit

Date: 12 Jan 2018

Chinese conglomerate Fosun Group is kicking off its overseas investment in 2018 with a plan to set up a U.S. subsidiary to produce pharmaceuticals and develop medical-device businesses.

The unnamed new company — involving an investment of $50 million — will manufacture drugs targeting overseas markets, and develop a line of medical devices and medical diagnosis businesses, according to a statement 10 Jan from Fosun’s pharmaceutical unit, Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

The new subsidiary will be jointly held by Fosun’s investment body, Fosun International Ltd., and its established U.S. unit, Fosun Pharma USA Inc., according to the Fosun Pharma statement.

Pharmaceuticals have been Fosun’s core business since the 1990s. The company expanded overseas in recent years mainly through mergers and acquisitions. Some of its deals last year included taking majority stakes in Swedish respiratory machine-maker Goldcup and Indian drugmaker Gland Pharma.

Beijing has warned dealmakers to moderate their investment risks. Commercial banks were ordered last year to study bad-loan risks involving companies, including Fosun. Nevertheless, Fosun has sought to increase overseas investments in insurance, pharmaceuticals and resorts.

Fosun International will continue to invest in companies according to three themes — “health, wealth and recreation” — with specific interest in Europe and the U.S., the company said during an earnings meeting in August 2017.

It also expressed interest in buying startups valued at $1 billion or above, and is interested in healthcare companies that employ artificial intelligence technology.

Source: Caixin

Disclaimer
The information on this page may have been provided by a contributor to ChinaGoAbroad, and ChinaGoAbroad makes no guarantees about the accuracy of any content. All content shall be used for informational purposes only. Contributors must obtain all necessary licenses and/or ownership rights from the relevant content owner(s) before submitting the same to ChinaGoAbroad for publication. ChinaGoAbroad disclaims all liability arising from the publication of content received from contributors. Links may direct to third party sites out of the control of ChinaGoAbroad, and such links shall not be considered an endorsement by ChinaGoAbroad of any information contained on such third party sites. Please refer to our Disclaimer for more details.
Top